



Adherium Delivers First Order of Hailie Smart Inhaler Sensors to US Intermountain Health

Melbourne, Australia – 18 December 2023: Adherium Limited (ASX:ADR) a leader in digital health technologies has delivered the first purchase order agreement of 1,750 of its next generation Hailie® Smartinhaler® sensors to major US hospital system, Intermountain Health.

This sale reflects Adherium's recently announced commercialisation focus on strategic, value sharing partnerships with large scale US healthcare providers and insurers.

Intermountain includes 33 hospitals, 385 clinics with more than 12,000 associated physicians. Intermountain is a leader in outpatient respiratory care with around 300,000 chronic obstructive pulmonary disease (COPD) and asthma patients.

Hailie's unique next generation sensors remotely capture when and how an inhaler is being used, profoundly improving adherence and patient self-management. This data enables timely interventions and tailored treatments to improve health outcomes to reduce hospital admissions and ultimately healthcare costs.

The advanced features of the next generation Hailie sensors include inhalation flow rate, inspiratory flow duration, inhaled volume and other metrics which are valuable information about patients' prescribed medication reaching their lungs. Hailie is the only US FDA 510(k) cleared, drug-agnostic digital sensor available today providing physiological data insights on inhaler technique.

Intermountain Health's purchase of Hailie Smartinhalers is part of their commitment to improving patient experiences and health outcomes through integrating emerging e-health technology.

Hailie enables doctors to bill for long-term, remote patient management under established US reimbursement codes. Adherium is paid for sensor sales and receives monthly, per patient fees for generating and transmitting respiratory data.

"We are delighted with this significant purchase from Intermountain Health further expanding our footprint and establishing a new strategic partner in the US market," said Rick Legleiter, CEO of Adherium.

"It's pleasing to see the growing recognition and trust in the value of Adherium's respiratory health technology."

-ENDS-

This ASX announcement was approved and authorised for release by the Board of Adherium.

Enquiries:
Rick Legleiter
CEO
Adherium Limited
investors@adherium.com

About Adherium (ASX: ADR)

Adherium Limited (ASX: ADR) is a digital health company providing solutions for improving patient treatment with remote monitoring and data solutions. Its Hailie® system is transforming management of chronic respiratory conditions, especially asthma and chronic obstructive pulmonary disease. Hailie improves patient health through better adherence and self-management while enabling doctors to be paid for remote work and saving costs across health systems by avoiding hospital admissions. Adherium's clinically proven sensors, app and powerful data platform provide remote, real-time, personalised information to patients and clinicians. Adherium is increasing sales in US and other markets by pursuing partnerships with major hospital systems, medical groups and insurers. For more information, visit <https://www.adherium.com/>.

About Intermountain Health

Intermountain Health is a team of nearly 60,000 employees who serve the healthcare needs of people across the Intermountain West, primarily in Utah, Idaho, Nevada, Colorado, Montana, Wyoming and Kansas. Intermountain Health is an integrated, non-profit health system based in Salt Lake City, with clinics, a medical group, affiliate networks, hospitals, homecare, telehealth, health insurance plans and other services, along with wholly owned subsidiaries including SelectHealth, Saltzer Health, Castell, Tellica and Classic Air Medical.

Intermountain currently cares for hundreds of thousands of patients living with chronic respiratory diseases such as COPD and asthma.